Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Blood marker for early diagnosis of dengue and dengue hemorrhagic fever

A technology for dengue hemorrhagic fever and dengue fever, which is applied in biological testing, biochemical equipment and methods, and microbial measurement/testing, and can solve the problems of complex clinical manifestations and difficult diagnosis of dengue virus infection

Inactive Publication Date: 2018-07-31
QINGDAO MEDINTELL BIOMEDICAL CO LTD
View PDF2 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0011] The clinical manifestations of dengue virus infection are very complex, and most of the symptoms are indistinguishable from diseases such as malaria, typhoid fever, and chikungunya fever. It is difficult to make a clear diagnosis based solely on the epidemiological data and clinical manifestations of patients, so laboratory tests are required for further diagnosis

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Blood marker for early diagnosis of dengue and dengue hemorrhagic fever
  • Blood marker for early diagnosis of dengue and dengue hemorrhagic fever

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0060] Example 1 Screening of genes differentially expressed in patients with dengue fever and / or dengue hemorrhagic fever and normal people

[0061] 1. Research object:

[0062]Disease group: Collect 5 patients with dengue fever, 5 patients with dengue hemorrhagic fever, all patients according to "WHO / TDR.Dengue-Guidelines for diagnosis, Treatment, prevention and control.2009; http: / / www.who.int / tdr / publications / training-guideline-publications / dengue-diagnosis-treatment / en / index.html.Date of Access: 12 / 05 / 2015.2009" for diagnosis.

[0063] Normal group: 4 healthy volunteers were selected.

[0064] There was no significant difference in age and gender between the two groups (P>0.10), which were comparable.

[0065] All research subjects were informed about this study and signed the informed consent.

[0066] 2. Extraction of total RNA in blood

[0067] (1) Fresh whole blood, erythrocyte lysate (1:1), mix by inverting several times, let stand for 5 minutes. 10000g, 4°C, 1...

Embodiment 2

[0084] Example 2 Reverse transcription PCR experiment verifies the genes differentially expressed in patients with dengue fever and / or dengue hemorrhagic fever and normal people

[0085] The differentially expressed gene-AKT1 gene screened out in Example 1 was selected for large sample verification.

[0086] 1. Research object:

[0087] Disease group: 30 patients with dengue fever and 25 patients with dengue hemorrhagic fever were collected, all patients were collected according to "WHO / TDR.Dengue-Guidelines for diagnosis, Treatment, prevention and control.2009; http: / / www.who.int / tdr / publications / training-guideline-publications / dengue-diagnosis-treatment / en / index.html.Date of Access: 12 / 05 / 2015.2009" for diagnosis.

[0088] Normal group: select 30 cases of healthy volunteers.

[0089] There was no significant difference in age and gender between the two groups (P>0.10), which were comparable.

[0090] All research subjects were informed about this study and signed the inf...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses a gene marker for the early diagnosis of dengue and dengue hemorrhagic fever. The gene marker is an AKT1 gene. Whether a human subject suffers from the dengue and dengue hemorrhagic fever or whether the human subject has the risk of suffering from the dengue and dengue hemorrhagic fever is judged by detecting the levels of the AKT1 gene and an AKT1 protein in the blood of the human subject. A product for diagnosing the dengue and dengue hemorrhagic fever by detecting the content of the AKT1 gene or the AKT1 protein is developed according to the AKT1 gene and the AKT1 protein, and the diagnosis product can be popularized and used clinically.

Description

technical field [0001] The invention belongs to the field of epidemiological diagnosis and prevention, and relates to an AKT1 gene for diagnosing dengue fever and dengue hemorrhagic fever and its application. Background technique [0002] Since the Antonine plague (Shrap R, Lotka A J.A Problem in AgeDistribution[J].Philosophical Magazine, 1911,21:35-438) in the 2nd century AD, infectious diseases have been endangering human health and brought huge impacts on social stability. Impact. In recent years, the incidence of dengue infectious disease has increased rapidly and has become a world public health problem, and it is recorded as a disease in Appendix II of the newly revised International Health Regulations (2005). Dengue fever is an acute infectious disease caused by dengue virus and transmitted by Aedes mosquitoes. At first, people named it joint fever and fracture fever according to its symptoms (Monath, T.P. Dengue: The risk to developed and developing countries: Proc...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): C12Q1/6883G01N33/68
CPCC12Q1/6883C12Q2600/158G01N33/6893Y02A50/30
Inventor 贾宏毅向常娟
Owner QINGDAO MEDINTELL BIOMEDICAL CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com